RxDoctor Payments Data

Mohammed Alam, MD

Geriatric Medicine · Stony Brook, NYNPI 1730264441

Payments from drug & device makers

$603in general payments, 2019–2025

Across 21 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$292
  • Urovant Sciences Inc$125
  • AstraZeneca$76
  • Edwards Lifesciences$48
  • Boehringer Ingelheim$23
  • Molnlycke Health Care US, LLC$21
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$603100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$603 in reported general payments places this provider in the 75th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$84,992
Medicare patients
118
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$70,298
MyrbetriqMirabegron21$8,827
SantylCollagenase Clostridium Hist.18$5,954
Cyclosporine16$4,478
ErtapenemErtapenem Sodium11$3,792
Oseltamivir Phosphate57$3,283
Memantine Hcl ErMemantine Hcl30$2,943
Potassium Chloride105$2,887
PradaxaDabigatran Etexilate Mesylate21$2,144
Enoxaparin Sodium17$1,925
Tamsulosin Hcl150$1,870
NovologInsulin Aspart23$1,867
LantusInsulin Glargine,hum.Rec.Anlog21$1,540
Atorvastatin Calcium170$1,487
Arnuity ElliptaFluticasone Furoate12$1,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimPradaxa$23$2,14421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →